ACP-103, a 5-HT2A receptor inverse agonist: Safety, tolerability, and pharmacokinetics in healthy volunteers

被引：0
|
作者：
Vanover, KE
Weiner, DM
Schlienger, N
Thygesen, M
Tolf, B
Hacksell, U
Brann, MR
Davis, RE
机构：
来源：
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | 2004年 / 7卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S253 / S253
页数：1
相关论文
共 50 条
  • [21] Pimavanserin, a 5-HT2A inverse agonist, potentiates the efficacy and tolerability of risperidone in the treatment of schizophrenia
    Meltzer, Herbert Y.
    BIOLOGICAL PSYCHIATRY, 2008, 63 (07) : 139S - 139S
  • [22] Pharmacokinetics, pharmacodynamics, safety and tolerability of cilofexor, a novel nonsteroidal Farnesoid X receptor agonist, in healthy volunteers
    Younis, Islam R. R.
    Kirby, Brian J. J.
    Billin, Andrew N. N.
    Xiao, Deqing
    Song, Qinghua
    Watkins, Timothy R. R.
    Othman, Ahmed A. A.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2023, 16 (03): : 536 - 547
  • [23] A Novel Synthesis of Pimavanserin: A Selective Serotonin 5-HT2A Receptor Inverse Agonist
    Hu, Kun
    Zhang, Meiju
    Wu, Dongdong
    Xie, Yuxuan
    Ren, Jie
    ORGANIC PREPARATIONS AND PROCEDURES INTERNATIONAL, 2020, 52 (01) : 69 - 76
  • [24] ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models
    Gardell, Luis R.
    Vanover, Kimberly E.
    Pounds, Linda
    Johnson, Robert W.
    Barido, Richard
    Anderson, Gary T.
    Veinbergs, Isaac
    Dyssegaard, Agnete
    Brunmark, Per
    Tabatabaei, Ali
    Davis, Robert E.
    Brann, Mark R.
    Hacksell, Uli
    Bonhaus, Douglas W.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2007, 322 (02): : 862 - 870
  • [25] Inverse agonist activity of sarpogrelate, a selective 5-HT2A-receptor antagonist, at the constitutively active human 5-HT2A receptor
    Muntasir, Habib Abul
    Bhuiyan, Mohiuddin Ahmed
    Ishiguro, Masaji
    Ozaki, Masanobu
    Nagatomo, Takafumi
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2006, 102 (02) : 189 - 195
  • [26] Comparison of cortical 5-HT2A receptor binding in bulimia nervosa patients and healthy volunteers
    Goethals, I
    Vervaet, M
    Audenaert, K
    Van de Wiele, C
    Ham, H
    Vandecapelle, M
    Slegers, G
    Dierckx, R
    van Heeringen, C
    AMERICAN JOURNAL OF PSYCHIATRY, 2004, 161 (10): : 1916 - 1918
  • [27] SAFETY, TOLERABILITY AND PHARMACOKINETICS OF ADL5859, A NOVEL DELTA OPIOID RECEPTOR AGONIST (DORA), IN HEALTHY HUMAN VOLUNTEERS
    Leese, P.
    Schomer, D.
    Berger, B.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 : S41 - S41
  • [28] The 5-HT2A/1A agonist psilocybin reduces social pain and enhances empathy in healthy volunteers
    Preller, K. H.
    Pokorny, T.
    Kraehenmann, R.
    Scheidegger, M.
    Dziobek, I.
    Staempfli, P.
    Vollenweider, F. X.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2015, 25 : S301 - S301
  • [29] The 5-HT2A/1A Agonist Psilocybin Enhances Empathy and Reduces Social Pain in Healthy Volunteers
    Preller, Katrin H.
    Pokorny, Thomas
    Kraehenmann, Rainer
    Dziobek, Isabel
    Staempfli, Philipp
    Vollenweider, Franz X.
    BIOLOGICAL PSYCHIATRY, 2015, 77 (09) : 134S - 135S
  • [30] Pharmacokinetics, safety, and tolerability of single intravenous infusions of an adenosine agonist, AMP 579, in healthy male volunteers
    Zannikos, PN
    Baybutt, RI
    Boutouyrie, BX
    Shah, B
    Hunt, TL
    Jensen, BK
    JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 39 (10): : 1044 - 1052
12345